NEUROTECH INTERNATIONAL LIMITED Financials Neurotech International Limited
Equities
NTI
AU000000NTI9
Advanced Medical Equipment & Technology
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.091 AUD | 0.00% |
|
-1.09% | +31.88% |
| 04-17 | Neurotech's Phase II/III NTIASD2 Clinical Trial for Children with Autism Meets Primary Endpoint | MT |
| 04-17 | Neurotech International Completes AU$10 Million Capital Raise | MT |
Valuation
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 17.44 | 2.443 | 1.722 | 36.93 | 48.84 | 34.96 |
| Enterprise Value (EV) 1 | 15.26 | 2.095 | 1.764 | 32.1 | 46.94 | 29.93 |
| P/E ratio | -4.07 x | -0.44 x | -0.72 x | -3.51 x | -14.5 x | -4.1 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 580 x | 9.94 x | 21.4 x | 164 x | 80.4 x | 29.3 x |
| EV / Revenue | 508 x | 8.52 x | 22 x | 142 x | 77.3 x | 25.1 x |
| EV / EBITDA | -4.21 x | -0.75 x | -1.37 x | - | -14 x | -3.81 x |
| EV / FCF | -6.21 x | -1.35 x | -5.72 x | -370 x | -27.2 x | -8.72 x |
| FCF Yield | -16.1% | -74.3% | -17.5% | -0.27% | -3.67% | -11.5% |
| Price to Book | 4.12 x | 8.22 x | -2.66 x | 9.57 x | 34.2 x | 8.82 x |
| Nbr of stocks (in thousands) | 109,012 | 135,744 | 215,216 | 696,819 | 697,699 | 873,909 |
| Reference price 2 | 0.1600 | 0.0180 | 0.008000 | 0.0530 | 0.0700 | 0.0400 |
| Announcement Date | 02/09/18 | 30/08/19 | 31/08/20 | 29/08/21 | 31/08/22 | 30/08/23 |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.03 | 0.2458 | 0.0803 | 0.2255 | 0.6076 | 1.194 |
| EBITDA 1 | -3.624 | -2.794 | -1.29 | - | -3.361 | -7.85 |
| EBIT 1 | -3.749 | -2.796 | -1.292 | -7.429 | -3.361 | -7.852 |
| Operating Margin | -12,477.76% | -1,137.31% | -1,607.55% | -3,293.95% | -553.2% | -657.31% |
| Earnings before Tax (EBT) 1 | -3.99 | -4.802 | -1.713 | -7.431 | -3.362 | -7.792 |
| Net income 1 | -3.99 | -4.802 | -1.713 | -7.431 | -3.362 | -7.792 |
| Net margin | -13,280.17% | -1,953.44% | -2,132.71% | -3,294.65% | -553.35% | -652.32% |
| EPS 2 | -0.0393 | -0.0406 | -0.0111 | -0.0151 | -0.004821 | -0.009754 |
| Free Cash Flow 1 | -2.457 | -1.557 | -0.3084 | -0.0868 | -1.724 | -3.432 |
| FCF margin | -8,177.1% | -633.2% | -383.82% | -38.49% | -283.7% | -287.34% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 02/09/18 | 30/08/19 | 31/08/20 | 29/08/21 | 31/08/22 | 30/08/23 |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 0.04 | - | - | - |
| Net Cash position 1 | 2.18 | 0.35 | - | 4.83 | 1.9 | 5.03 |
| Leverage (Debt/EBITDA) | - | - | -0.0324 x | - | - | - |
| Free Cash Flow 1 | -2.46 | -1.56 | -0.31 | -0.09 | -1.72 | -3.43 |
| ROE (net income / shareholders' equity) | -93.6% | -212% | 982% | -462% | -127% | -289% |
| ROA (Net income/ Total Assets) | -49% | -66.4% | -220% | -183% | -59.8% | -134% |
| Assets 1 | 8.139 | 7.227 | 0.7786 | 4.07 | 5.625 | 5.821 |
| Book Value Per Share 2 | 0.0400 | 0 | -0 | 0.0100 | 0 | 0 |
| Cash Flow per Share 2 | 0.0200 | 0 | 0 | 0.0100 | 0 | 0.0100 |
| Capex 1 | 0.1 | - | - | - | 0 | - |
| Capex / Sales | 325.63% | - | - | - | 0.53% | - |
| Announcement Date | 02/09/18 | 30/08/19 | 31/08/20 | 29/08/21 | 31/08/22 | 30/08/23 |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +31.88% | 60.13M | |
| +3.59% | 3.48B | |
| -5.85% | 174M | |
| -14.17% | 82.89M |
- Stock Market
- Equities
- NTI Stock
- Financials Neurotech International Limited
